Suppr超能文献

序贯静脉注射/口服环丙沙星加甲硝唑与静脉注射头孢曲松加甲硝唑治疗复杂性腹腔内感染的比较。

Comparison of sequential intravenous/oral ciprofloxacin plus metronidazole with intravenous ceftriaxone plus metronidazole for treatment of complicated intra-abdominal infections.

作者信息

Wacha Hannes, Warren Brian, Bassaris Harry, Nikolaidis Paul

机构信息

Department of Surgery, Academic Hospital of the University of Frankfurt, Frankfurt-am-Main, Germany.

出版信息

Surg Infect (Larchmt). 2006 Aug;7(4):341-54. doi: 10.1089/sur.2006.7.341.

Abstract

BACKGROUND AND PURPOSE

Intra-abdominal infections are a substantial clinical problem and an important cause of morbidity and death in the hospital. Optimal treatment requires both source control and antibiotic therapy. Sequential intravenous (IV) to oral therapy may improve patient convenience and reduce total health care costs. In this randomized, double-blind trial, the efficacy of sequential IV-to-oral ciprofloxacin plus metronidazole was compared with ceftriaxone plus metronidazole in adult patients with complicated intra-abdominal infections.

METHODS

The trial enrolled 531 patients, who began with IV therapy. Patients who improved clinically were switched to oral therapy on day three or later. The clinical and bacteriological responses four to six weeks after the end of therapy and the safety of the two regimens were assessed. To maintain blinding, the patients received placebo IV in the ciprofloxacin group or placebo orally in the ceftriaxone group. A total of 475 patients (235 ciprofloxacin plus metronidazole, 240 ceftriaxone plus metronidazole) were valid for evaluation of efficacy. All patients were included in the safety analysis.

RESULTS

Of the patients valid for efficacy, 78% of the ciprofloxacin plus metronidazole group and 81% of the ceftriaxone plus metronidazole group were eligible for a switch to oral therapy. The clinical success rates were 98.9% and 96.9%, respectively, which were statistically equivalent. The clinical success rates for all patients, including those on continuous IV therapy, were 90.6% and 87.9%. Source control was achieved in more than 90% of the patients. The bacteriological eradication rates were similar in the two groups. Bacterial complications (e.g., surgical site infections, abscesses) were encountered more often in the ceftriaxone plus metronidazole group.

CONCLUSIONS

Sequential ciprofloxacin plus metronidazole IV-to-oral therapy was statistically equivalent to ceftriaxone plus metronidazole. The switch to oral therapy with ciprofloxacin plus metronidazole was as effective and safe as continued IV therapy in patients able to tolerate enteral feeding.

摘要

背景与目的

腹腔内感染是一个严重的临床问题,也是医院发病和死亡的重要原因。最佳治疗需要源头控制和抗生素治疗。序贯静脉给药改为口服给药治疗可能会提高患者的便利性并降低总体医疗成本。在这项随机双盲试验中,对序贯静脉给药改为口服环丙沙星加甲硝唑与头孢曲松加甲硝唑治疗成人复杂性腹腔内感染的疗效进行了比较。

方法

该试验纳入了531例开始接受静脉治疗的患者。临床症状改善的患者在第3天或之后改为口服治疗。评估治疗结束后4至6周的临床和细菌学反应以及两种治疗方案的安全性。为保持盲法,环丙沙星组患者接受静脉注射安慰剂,头孢曲松组患者接受口服安慰剂。共有475例患者(235例环丙沙星加甲硝唑,240例头孢曲松加甲硝唑)可用于疗效评估。所有患者均纳入安全性分析。

结果

在可评估疗效的患者中,环丙沙星加甲硝唑组78%的患者和头孢曲松加甲硝唑组81%的患者符合改为口服治疗的条件。临床成功率分别为98.9%和96.9%,在统计学上相当。包括持续接受静脉治疗的患者在内,所有患者的临床成功率分别为90.6%和87.9%。超过90%的患者实现了源头控制。两组的细菌清除率相似。头孢曲松加甲硝唑组更常出现细菌并发症(如手术部位感染、脓肿)。

结论

序贯环丙沙星加甲硝唑静脉给药改为口服治疗在统计学上与头孢曲松加甲硝唑相当。对于能够耐受肠内喂养的患者,改为口服环丙沙星加甲硝唑治疗与持续静脉治疗同样有效且安全。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验